Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | F2RL1 | P55085 | 8/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2831573 | 0.97 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2NISCHMTORADK | |
| SCHEMBL4363951 | 0.81 | MTOR (0.47) | NISCHMTORADKADRA2AADRA2B | |
| SCHEMBL2576594 | 0.80 | — | — | |
| SCHEMBL1905054 | 0.80 | — | — | |
| SCHEMBL7406986 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL25337587 | 0.78 | ADRA2A (0.45) | ALDH1A1SMN1; SMN2NISCHMTORADK | |
| Hydrochloric Acid SCHEMBL29908311 | 0.78 | — | — | |
| SCHEMBL2469423 | 0.78 | FPR2 (0.42) | ADRA2AADRA2BADRA2CF2RL1FPR2 | |
| SCHEMBL2472566 | 0.78 | FPR2 (0.43) | NISCHMTORADKADRA2AADRA2B | |
| SCHEMBL2471280 | 0.78 | NISCH (0.50) | ALDH1A1SMN1; SMN2NISCHMTORADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150110716-A1 | METHODS OF USING SPECT/CT ANALYSIS FOR STAGING CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | US | claimed |
| EP-1189889-B1 | COMPOSITIONS AND METHODS FOR INHIBITING CELL DEATH | ELAN PHARMA INT LTD (IE) | 2003-12-17 | — | — | EP | claimed |
| CN-117820098-A | Method for preparing linear aldehyde by olefin selective hydroformylation | 复旦大学 | 2024-04-05 | — | — | CN | disclosed |
| EP-3057620-A2 | METHODS OF USING SPECT/CT ANALYSIS FOR STAGING CANCER | Molecular Insight Pharmaceuticals, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058151-A2 | METHODS OF USING SPECT/CT ANALYSIS FOR STAGING CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150110716-A1 | METHODS OF USING SPECT/CT ANALYSIS FOR STAGING CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| EP-1189889-B1 | COMPOSITIONS AND METHODS FOR INHIBITING CELL DEATH | ELAN PHARMA INT LTD (IE) | 2003-12-17 | — | — | EP | disclosed |
| US-6541486-B1 | Used for treating ischemia, such as results from stroke or myocardial infarction, trauma, neurodegeneration, and inflammation. | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2003-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150110716-A1 | METHODS OF USING SPECT/CT ANALYSIS FOR STAGING CANCER | KLK3, SHBG, FOLH1 | ALDH1A1 2956/4885SMN1; SMN2 4018/4885NISCH 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.